Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 24 (1) , 563-569
Abstract
To assess from a US payer perspective the relative cost-effectiveness of the catechol-O-methyltransferase inhibitors opicapone and entacapone when used adjunctively to levodopa/carbidopa (LD/CD) in...Keywords
This publication has 21 references indexed in Scilit:
- Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicineMovement Disorders, 2018
- Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson’s Disease Patients? A Systematic ReviewJournal of Parkinson’s Disease, 2018
- International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's diseaseMovement Disorders, 2018
- Neuropathology of Parkinson diseaseParkinsonism & Related Disorders, 2018
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trialThe Lancet Neurology, 2016
- Parkinson's diseaseThe Lancet, 2015
- Clinical spectrum of levodopa‐induced complicationsMovement Disorders, 2014
- Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamicsMovement Disorders, 2014
- Impact of the motor complications of Parkinson's disease on the quality of lifeMovement Disorders, 2004
- Dyskinesias and motor fluctuations in Parkinson's diseaseBrain, 2000